Please login to the form below
Data by
22
Revenue 2014Daiichi Sankyo
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.
FDA fast-tracks Astellas' Rydapt rival
If approved, the Japanese pharma group would see its drug not only compete with Rydapt - the first new drug for AML in more than 25 years - but also with Daiichi
Xarelto no better than aspirin in secondary stroke study
For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s
Novartis gets EU nod for leukaemia drug Rydapt
The FLT3 inhibitor adds to its US approval in AML
Astellas extends phase III programme for Rydapt rival gilteritinib
Two other FLT3 inhibitors - Daiichi Sankyo's quizartinib and Arog Pharma's crenolanib - are also in late-stage testing.
Daiichi drug hits mark in shingles pain, but misses in other indications
Daiichi Sankyo's mirogabalin has shown efficacy in a phase III trial involving patients with post-herpetic neuralgia (PHN), the persistent and often excruciating pain that can follow shingles. ... What is clear however is that the results of the ALDAY
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| Japan revenue 2014 |
|---|
| 1: Takeda |
| 2: Otsuka |
| 3: Meiji |
| 4: Astellas |
| 5: Daiichi Sankyo |
| 6: Teijin |
| 7: Eisai |
| 8: Chugai |
| 9: Mitsubishi Tanabe |
| 10: Kyowa Hakko Kirin |
| 11: Taisho |
| 12: Shionogi |
| 13: Hisamitsu |
| 14: Santen |
| 15: Ono |
| 16: Kyorin |
| 17: Nichi-Iko |
| 18: Mochida |
| 19: Sawai |
| 20: Kaken |
| 21: Kissei |
| 22: Zeria |
| 23: Towa |
| 24: Torii |
| 25: Daito |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| Cardiovascular revenue 2014 |
|---|
| 1: AstraZeneca |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Daiichi Sankyo |
| 5: Pfizer |
| 6: Novartis |
| 7: Bayer |
| 8: Takeda |
| 9: Boehringer Ingelheim |
| 10: Astellas |
| 11: Actelion |
| 12: Johnson & Johnson |
| 13: Shionogi |
| 14: United Therapeutics |
| 15: Bristol-Myers Squibb |
| 16: Gilead Sciences |
| 17: Otsuka |
| 18: Roche |
| 19: Lilly |
| 20: The Medicines Company |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
-
Account Director at PAREXEL MedCom
-
Competitive Salary
-
Editorial Director - BioScience
-
Competitive Salary
-
Principal Medical Writer
-
Great salary and benefits
- Scientific Director, Medical Communications
-
£60 – 70, 000 benefits
- Digital Account Director – Healthcare Communications
-
£50 – 60, 000 benefits
- Scientific Team Leader, Medical Education
-
£55, 000 – £70, 000 benefits
- Account Director, Healthcare Communications
-
£50, 000 - £60, 000
-
Account Director
-
Salary TBC
-
Medical Editor
-
Great salary and benefits
Subscribe to our email news alerts
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- Tools for the digital world
- The next step for the pharma industry...
- How Can We Make Payer Communications Really Sing?
- With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
- Harnessing the power of core elements to optimise market access
- This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
Quick links
Infographics
